FindTrial
Sign In

Comparing injection ondansetron with injection granisetron to prevent nausea and vomiting in patients after laparoscopic surgeries.

A COMPARATIVE STUDY OF EFFICACY OF ONDANSETRON AND GRANISETRON FOR PREVENTION OF NAUSEA AND VOMITING FOLLOWING ELECTIVE LAPAROSCOPIC SURGERIES: A PROSPECTIVE RANDOMISED DOUBLE BLINDED STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032553
Enrollment
100
Registered
2021-04-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K353- Acute appendicitis with localizedperitonitis Health Condition 2: K353- Acute appendicitis with localizedperitonitis Health Condition 3: K37- Unspecified appendicitis Health Condition 4: K37- Unspecified appendicitis

Interventions

Intervention1: Injection Ondansetron 4mg IV: Patients will receive 4mg inj Ondansetron slow iv over a period of 30 seconds at the end of the surgery before extubation. Intervention2: Injection Granise

Sponsors

S N Medical College and HSK Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. ASA physical status I to II. 2. Age between 18 to 50 years. 3. Patients undergoing elective laparoscopic surgeries.

Exclusion criteria

Exclusion criteria: 1.Patient refusal 2.Pregnant women 3.Emergency surgeries 4.BMI more than 30 kg/m2 5.History of drug allergy 6.History of motion sickness

Design outcomes

Primary

MeasureTime frame
Comparison of the efficacy of prophylactic administration of Ondansetron with that of Granisetron in preventing PONV in patients undergoing elective laparoscopic surgeries.Timepoint: Episodes of nausea and vomiting experienced will be noted during the periods 0-4hrs, 4-12hrs, 12-24hrs.—

Secondary

MeasureTime frame
The side effects of Ondansetron and GranisetronTimepoint: Any adverse reactions of the drug like headache, dizziness, hypersensitivity, constipation if any will be noted in the 24 hr study period.—

Countries

India

Contacts

Public ContactDr Roopa Holkunde

S.Nijalingappa Medical College

drroopabannale@gmail.com9632276460

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026